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CHAPTER 1: INTRODUCTION 
Nutrigenomics is the scientific study of the specific way in which specific genes interact 
with bioactive food components and affect the genome without altering DNA structure [1]. 
Nutrigenomics allows nutritionists and microbiologists to elucidate the mechanisms by which 
nutrients have an impact on the genome [1]. It is important to investigate how several cellular 
processes in the human body can be modified by foods that interact with gene expression. 
Nutrition affects brain structure, function and development throughout the life cycle and can 
have profound implication on cognition, mental health and degenerative diseases [2]. 
Neurodegenerative diseases affect more than 30 million people throughout the world causing 
mental disability and death. There are essential and nonessential nutrients that are known to have 
an impact on metabolism, hormonal balance, energy balance, cell cycle signaling and regulation, 
apoptosis and angiogenesis [3].  Dietary folate has become an interesting food component to 
study in the rising field of nutrigenomics.  Folate deficiency has been studied extensively due to 
its association with chronic diseases, such as Alzheimer’s disease, cancer and cardiovascular 
disease [4].  
A. Folate  
 
Folate is an essential water soluble vitamin that plays a role in several mechanisms and 
pathways in relevance to etiologies of birth defects and chronic diseases. Folate or folic acid is 
found to be available in most plant based foods, however it is often found to be under-consumed 
in the diets of individuals that eat low amounts of fruits and vegetables [5]. Folate is found in our 
diets as bioactive forms of fundamental B vitamins [6]. Folate is naturally available in foods as 
“pterolypolyglutamates”, and it is used in vitamin supplements and fortified food products in the 
form of “monoglutamate folic acid” [6]. Folic acid is the most stable and fully oxidized form of 
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folate and has a greater bioavailability, therefore it is the form used in fortified foods [7]. Folic 
acid acts as a coenzyme in the metabolism of amino acids and nucleic acids and plays an integral 
role in many cellular pathways, DNA and RNA synthesis, cellular replication, intracellular 
signaling and regulation of cell division [6, 7]. All of these processes are implicated in fetal and 
placental growth and development; therefore it is crucial to maintain the levels of this vitamin 
throughout the early stages of development and growth [6, 8]. For this reason, in 1998 the United 
States and Canada mandated folic acid fortification in staple food items such as most grains and 
cereal products [8].  
B. Neural Tube Defects (NTDs) 
Poor folate status in women of child-bearing age and pregnant women is known to cause 
NTDs, miscarriages, and premature births [8]. Neural tube defects involve the incomplete 
development of the embryonic structure that becomes the brain and/ or spinal cord; there are two 
common types of NTDs: spina bifida and anencephaly [9]. This defect occurs when the brain and 
spinal cord are left susceptible due to the due to the failure of the neural tubes closing [10]. 
Anencephaly is the most severe and spina bifida can cause a range of morbidities; which 
includes the paralysis of the lower limbs and urinary and fecal incontinence [11].  
The exact mechanism by which folate reduces the risk for NTDs still remains as a part of 
active research [11].The British Medical Research Council conducted a randomized control trial 
to determine the effectiveness of folic acid supplementation in the prevention of recurrence of 
NTDs; it was observed that by taking 4000 micrograms of folic acid the risk of NTD recurrence 
was reduced by 70% [11]. By 1992 the U. S Public Health Service recommended that women of 
child bearing age should consume 400 µg of folic acid daily through supplementation and diet to 
prevent NTDs [11]. However encouraging women to consume 400 µg of folic acid through 
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supplementation has limitations due to the fact that almost more than 50% of pregnancies in the 
United States are unplanned [11].  Therefore in 1998 a mandatory folic acid fortification was 
implemented to provide 140µg per 100g to all enriched cereal grain products and had been 
estimated to provide 100-200µg of folic acid to women of childbearing age [11].  A significant 
decrease in the prevalence of NTDs has been observed across the United States and many other 
countries since the mandatory implementation in 1998 of folic acid fortification [11].  
C. Potential Adverse Effects of Folate Fortification 
There are always concerns regarding adverse effect consequences to any type of public 
health intervention as it becomes critical to monitor any and all fortification programs to address 
any type of emerging concerns. With folic acid fortification, the main concerns that have been 
monitored are: 1.) Masking of B12 Deficiency Anemia, 2.) Cancer and Epigenetic Changes and 
3.) Unmetabolized Folic Acid.  
1.) Masking of B12 Deficiency Anemia 
Early case reports suggested that the consumption of folic acid in amounts <5000µg daily could 
possibly mask Vitamin B12 deficiency by preventing the development of anemia. If masked and 
not diagnosed at an early stage, this masking could allow for the progression of Vitamin B12 
deficiency related neuropathies. However several studies done prior to and after fortification, 
suggest that there is very little evidence of neuropathies [11].  
2.) Cancer and Epigenetic Changes  
Studies indicate that a diet high in the consumption of folate through fruits and vegetables can 
reduce the risk of certain types of cancers. As a result of this assumption studies are being 
conducted to elucidate the mechanism by which folate impacts epigenetic patterns. Folate plays a 
key role in two important epigenetic modifications-- DNA synthesis and methylation. Since 
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folate is involved as a one carbon methyl group in DNA methylation, studies are focusing on 
how it can positively or negatively affect any disease, especially tumorgenesis [11]. Some 
studies hypothesize that an early and adequate exposure to folic acid may prevent the 
development of tumor cells through the provision of enough methyl groups during DNA 
methylation. However other studies show that a higher intake of folic acid may promote the 
growth of pre-existing tumors [11]. Nonetheless, further studies must be conducted to determine 
the way in which folic acid has an impact on epigenetic patterns through a mechanistic approach. 
3.) Unmetaoblized Folic Acid  
An excess intake of folic acid can result from an increased consumption of fortified supplements 
and foods (such as cereal grain products).  If the body exceeds the capacity to metabolize folic 
acid, the folic acid will be found circulating in the blood [12].  Thus far it has been hypothesized 
that unmetablized folic acid is related to cognitive decline and impairment among seniors [12, 
13].  
D. Folate One-Carbon Metabolism 
As stated earlier, folic acid plays an integral role in many cellular pathways, including 
DNA and RNA synthesis, cellular replication, intracellular signaling and regulation of cell 
division [6, 7]. Folate is the central focus of the one-carbon metabolism pathway and plays in 
integral in the regulation of the pathway. The one- carbon metabolism pathway is displayed in 
the figure below:  
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Figure 1-1: Folate Metabolism [14] 
 A polyglutamyl form of the tetrahydrofolate (THF) group is the main factor involved in one-
carbon metabolism; this acceptor molecule is 5-methylenetetrahydrofolate (5-methyl THF) [15]. 
The most crucial step in the pathway to provide the 3 carbon serine (major carbon source) is the 
conversion of THF to 5, 10-methylene THF [15].  Serine uses this one-carbon unit to form 5, 10-
methylene-THF and glycine from THF via serine hydroxymethyltransferase (SHMT). The 
enzyme responsible for the irreversible conversion of 5, 10 methylene-THF to 5-methyl THF is 
methylenehydrofolate reductase (MTHFR). The N-5 methyl group of 5-methyl THF can only be 
used metabolically for transfer to homocysteine, which results in the regeneration of methionine; 
in the methionine synthase reaction, demethylation of the 5-methyl THF occurs and this methyl 
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group is sequentially transferred to the vitamin B-12 coenzyme before homocysteine, thus 
forming methionine [15].  The produced methionine is then broken down to the methyl donor 
group: s-adenosylmethionine (SAM), as demethylation continues, s-adenosyl-L-homocysteine 
(SAH) is converted into homocysteine.  Furthermore, the conversion of deoxyuridine 
monophosphate (dUMP) to thymidine monophosphate (dTMP) via the enzyme thymidylate 
synthase (TS) occurs during the pyrimidine biosynthesis pathway [16]. The most important 
functions involved in folate metabolism are: the transfer of one-carbon in the methionine cycle, 
the synthesis of purines (adenine and guanine) and the DNA methylation reactions. These 
reactions are a required to maintain the integrity of genetic material and sustain DNA 
proliferation. However this pathway can be altered when folate status is compromised and can 
lead to harmful epigenetic changes.  
 When folate status is compromised, several reactions in one-carbon metabolism are 
affected and can lead to negative consequences. The regulation of this pathway is tightly 
controlled by the synthesis of methyl groups and other one-carbon units; folate and relevant 
coenzymes are categorized between mitochondria and cytosol [16].  The inhibition of MTHFR 
by SAM can suppress the production of 5-methyl-THF; therefore the presence of excess methyl 
groups can further the de novo biosynthesis of methyl groups [16]. Inadequate folate status 
during severe deficiency can impair one-carbon metabolism, however since 5-methyl and 5-
formyl-THF play the role of SHMT inhibitors marginal deficiency may only effect the carbon 
flux marginally due to their effects being diminished [16].  In a low folate status condition, the 
regulation of SAM would be disrupted, the concentration of SAH would increase due to the 
failure of methyl group synthesis and homocysteine re-methylation [17].  
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E. Neurodegenerative Diseases  
 As stated earlier, inadequate folate intake during pregnancy increases the risk of 
abnormalities of the fetus.  Folate deficiency has also been associated with neurodegenerative 
conditions, such as Alzheimer’s disease (AD), Parkinson’s disease (PD), amyotrophic lateral 
sclerosis (ALS) and stroke in the elderly [18]. Folate deficiency alters SAM- dependent histone 
methylation. Compromised histone methylation has been associated with impaired learning and 
memory, intellectual disability, autism, and neurodegeneration [18]. A rise in homocysteine 
serum concentration and a decreased SAM/SAH ratio can impair cerebral function and interfere 
with cognitive function leading to dementia and Alzheimer’s disease [19].  
Alzheimer’s is a progressive neurodegenerative disease associated with brain shrinkage 
and loss of neurons, leading to loss of brain function. Alzheimer’s is characterized by loss of 
memory and language, irritability, confusion, dementia, aggressive moods and loss of 
physiological conditions [20]. A compromise in one-carbon metabolism can accompany and may 
be the possible cause of neurodegeneration of Alzheimer’s Diseases [18]. In individuals with 
Alzheimer’s disease, SAH levels are elevated and they competitively inhibit SAM-dependent 
reactions, which in turn reduces methylation reactions [18].  
Elevated homocysteine levels have also been reported to cause cognitive decline and 
depression in patients with Parkinson’s disease [21]. Parkinson’s disease is a progressive nervous 
system disease that impairs movement. Homocysteine has the capability to exert neurotoxic 
effects which can decrease the movement and function on neural cells; elevated levels of 
homocysteine may increase the risk of Parkinson’s disease by having a direct effect on 
dopaminergic neurons [21]. 
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Huntington’s disease (HD) is an inherited autosomal dominant neurodegenerative disease 
which does not have an effective treatment or cure. It is characterized by neuron loss, psychiatric 
disturbances and dementia [22]. Higher plasma levels of homocysteine have been observed in 
patients with HD. Due to the regulatory effects of folic acid on homocysteine metabolism, it has 
been suggested that folic acid supplementation maybe helpful in HD [23].  However it has not 
yet been established that folic acid supplementation can provide any type of therapeutic effects in 
patients with HD.  
The adverse effects of folate deficiency and elevated homocysteine levels on the 
developing central nervous system suggests that the alteration in one-carbon metabolism and 
homocysteine levels may play a role in the pathogenesis of age-related neurodegenerative 
diseases [24]. Homocysteine can damage, kill and promote the degeneration of neurons by 
impairing DNA repair; it has been suggested that elevated levels of homocysteine may increase 
the vulnerability of the CNS to neurodegenerative diseases [24]. 
F. mTOR Pathway 
 The mammalian target of rapamycin (mTOR) pathway responds to several environmental 
cues and integrates these signals to regulate cellular growth and homeostasis [25]. The mTOR 
pathway impacts most major cellular functions due to its regulation of basic cell functions of 
growth and proliferation [25].  The deregulation and/or alteration of this pathway occur in many 
human diseases, such as cancer, obesity type 2 diabetes and neurodegenerative diseases. mTOR 
is a serine/threonine protein kinase that belongs to the phosphoinositide 3-kinase (PI3K) family; 
it interacts with proteins to form two specific multi- complexes mTORC1 and mTORC2 [25].  
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Figure 1-2: Overview of mTORC1 and mTORC2 [25] 
The mTORC1 complex integrates inputs from intra and extra cellular environmental cues (stress, 
amino acids, energy status, and growth factors) to regulate processes of protein and lipid 
synthesis, energy metabolism, development and autophagy mainly [25]. The mTORC2 responds 
to growth factor signals to regulate cell survival and migration [26].  Both of the mTOR 
complexes have different sensitivities to rapamycin, along with different signaling of upstream 
input and downstream output [25].  The mTOR signaling network/pathway can be seen in the 
figure below: 
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Figure 1-3: mTOR signaling Network [28] 
The mTOR pathway responds to several environmental cues to impact most major 
cellular functions; basic cell functions of growth and proliferation.  mTORC1 is activated by the 
PI3K and AKT pathways and mTORC2 is activated via signaling from the RAS and RAF 
(protein kinases) pathways [26]. As seen in the diagram: mTORC1 is composed of mTOR, 
PRAS40, mLST8 and raptor (rapamycin-sensitive); mTORC2 is composed of mTOR, PRR5/5L, 
mSIN1, mLST8 and rictor (rapamycin-insensitive) [28]. TSC1/2 functions as a GTP-ase 
activating protein for the Ras homolog enriched in the brain- Rheb; it acts as a key upstream 
regulator of mTORC1 to activate kinase activity and it transmits signals that affect mTORC1 
(such as insulin and insulin-like growth factors) [28].  
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mTORC1 directly targets two translational initiation factors, 4E-BP1 and S6K1 by 
phosphorylating them to promote protein synthesis. The phosphorylation of S6K1 mediates the 
phosphorylation of and activates the 40S ribosomal protein S6 which in turn enhances translation 
of mRNA [29]. The phosphorylation of 4E-BP1 prevents it from binding to eIF4E (cap-binding 
protein), leading it to form the eIF4E complex required to mediate cap dependent translation [25, 
29].  Growth factors activate mTORC1 indirectly by suppressing TSC1/2 function through 
phosphorylation of TSC2 by PI3K/AKT/mTOR pathway; AKT signals phosphorylates and 
causes the dissociation from raptor [25, 30].  
By contrast the phosphorylation of TSC2 by AMPK due to low energy levels results in 
the activation of TSC1/2 thus inhibiting mTORC1 signaling and stimulating autophagy [25]. 
AMPK is a protein kinase which senses intracellular energy and becomes activated as a response 
to low nutrient availability and ATP depletion. REDD 1 is an upstream repressor of mTORC1 
and is induced by stress, hypoxia, serum and nutrient deprivation. Although still unclear, it has 
been hypothesized that REDD 1 acts to promote the GAP activity of TSC2 toward Rheb 
resulting in the accumulation of Rheb-GDP and subsequent repression of mTORC1 signaling 
[26].  
mTORC2 activates AKT via phosphorylation of the Ser473 form of AKT to indirectly 
regulate further activation of AKT [31].  This activation of AKT via mTORC2 signals positive 
feedback and could thereby indirectly activate mTORC1 [25, 31, 32]. Inositol polyphosphate 
multikinase (IPMK) is kinase that acts as a physiologic mTOR cofactor; it regulates nutrient 
amino acid signaling to mTORC1 [33]. IPMK uses its terminal amino acid sequence to stabilize 
the binding of raptor to mTOR in the mTORC1 complex [33].  
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G.mTOR and Neurodegenerative Diseases 
 Neurodegeneration is a condition in which the neurons of the brain lose structure and 
function, eventually leading to cell death. Alzheimer’s, Parkinson’s and Huntington’s disease are 
characterized by the accumulation of misfolded/toxic proteins and related neuronal death. As the 
mTOR pathway is involved in several pathways of programmed cell death (autophagy, apoptosis 
and necroptosis) it is implicated to be involved in the pathophysiology of neurodegenerative 
diseases [34]. The mTOR signaling pathway plays in important role memory formation, fear, and 
loss of cognition; it may be required in the hippocampus for synaptic plasticity and memory 
formation [35]. Disruption of mTOR signaling can lead to the prevention of long-term 
potentiation and memory retention [35]. 
 mTOR activation has been considered as a contributor to the progression of AD however 
the level of mTOR activity that is beneficial or detrimental in this condition has not been 
determined yet [35].  In mice, the survival of newborn neurons and dendritic density have been 
compromised by Beta-Amyloid (Aβ) due to the loss of AKT, mTOR, and p70S6K activity [36]. 
mTOR has been shown necessary for the formation of long-term memory in the amygdala; loss 
of mTOR function can impair memory consolidation [36]. Studies have shown that the activation 
of p70S6K has been associated with formation of hyper-phosphorylated tau and neurofibrillary 
accumulation. Aβ can be toxic to cells in brains of patients with AD, it can phosphorylate and 
activate mTOR and p70S6K in neuroblastoma cells and lymphocytes [35].  In murine models it 
has been found that the up-regulation of mTOR activity has been associated with long-term 
potentiation and synaptic plasticity [37].  Retinoblastoma tumor suppressor (RB1) inducible 
Coiled-Coil 1 (RB1CC1) is necessary for neurite growth maintenance of mTOR signaling. If 
there is an insufficiency of RB1CC1 expression, it can result in mTOR activity inhibition, and 
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thereby cause neuronal atrophy in patients with AD [37, 38]. Overall, there is growing evidence 
demonstrating that the Aβ exerts its toxicity via the mTOR pathway, further supporting the idea 
that reducing mTOR signaling in AD may be a valid therapeutic approach. 
The level of mTOR signaling that can benefit or harm the condition of PD has also not 
been defined. It has been suggested that the inhibition of mTOR activity may be detrimental in 
PD [38]. Studies have shown that the expression of REDD1 is increased in Parkinson’s brains 
(animal models), leading to the death of dopaminergic neurons [38]. Along with this, if the 
downstream effector, 4E-BP1 is activated by leucine-rich repeat kinase 2 (LRRK2), it can alter 
protein translation resulting in the loss of dopaminergic neurons [38, 39]. However there are 
studies that show mTOR inactivation may preserve dopaminergic neurons. Animal models using 
rapamycin as a possible therapeutic approach show that the signaling pathway of AKT maybe 
providing neuronal protection [40]. A decrease was observed in the loss of dopaminergic neurons 
due to the inhibition of mTOR signaling as a result of autophagy pathway activation [38, 41]. 
Animal models using rapamycin as a possible therapeutic approach show that the signaling 
pathway of AKT maybe providing neuronal protection. It was believed that the inhibition of 
mTOR signaling was a result of autophagy pathway activation [41]. 
In HD, it has been found that the inhibition of mTOR pathway via autophagy promoting 
factors may be a possible treatment. Autophagy is responsible for clearing intracellular 
huntingtin protein aggregates that can lead to neuronal degeneration therefore considered 
important [42]. In fly and murine models, it has been found that rapamycin inhibits mTOR 
activity by increasing the autophagic clearance of proteins with long polyglutamine or 
polyalanine expansions, thereby attenuating huntingtin accumulation and cell death in HD [42, 
43]. However in some experimental models of HD, the inhibition of both mTOR complexes may 
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be needed to affect autophagy and the accumulation of huntingtin aggregates [42]. Studies show 
that a decrease in activity of p70S6K can protect against early decline in motor skills without 
having an effect on huntingtin protein levels [42]. Another study observed that the DNA damage 
protein 34 (GADD34) may be required for mTOR to provide neuroprotection in HD. GADD34 
function leads to dephosphorylation of TSC2 and induction of autophagy, thereby increasing cell 
survival when it is overexpressed [42].  
The failure to induce autophagy or the over-enhancement of the pathway can be an 
underlying aspect of certain brain pathologies [44]. Autophagy-related genes (ATGs) are key 
regulators of the autophagy process; mTOR acts as a regulator by suppressing the autophagy 
pathway under nutrient-rich conditions [44].  The inhibition of the TSC1/TSC2 as a result of the 
effects of growth factors and nutrient deprivation on the mTOR pathway causes activation of the 
mTORC1 complex, thereby inhibiting autophagy [44]. The first studies linking autophagy to the 
CNS were performed in animals in which essential regulatory genes (ATG5 and ATG7) were 
genetically inactivated [44].  It was found that inactivation of these regulatory genes resulted in 
spontaneous neurodegeneration, spontaneous accumulation of protein aggregates, neuronal loss 
and premature death [44].   An experimental study tested a Beclin 1(+/-) known-down crossed 
into an AD mouse model, to find that Aβ accumulation was promoted, suggesting that autophagy 
of Aβ aggregates may be inhibited in AD [45]. Another experiment, using two AD mouse 
models treated with rapamycin for 10-13 weeks was conducted to determine the role of 
autophagy in AD; rapamycin was found to promote autophagy to decrease Aβ accumulation [45, 
46, 47].  These conflicting studies suggests there is a discrepancy in autophagy activity in the AD 
brain, therefore further studies must be conducted to elucidate this mechanism.  
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CHAPTER 2: SPECIFIC AIMS  
 The mTOR signaling pathway responds to several environmental cues and integrates 
these signals to regulate cell function, homeostasis and proliferation. The mTOR signaling 
pathway can impact multiple neurodegenerative diseases including Alzheimer’s, Parkinson’s and 
Huntington’s disease. mTOR signaling can affect the early development of cells through stem 
cell proliferation and differentiation as well as the end stages of cellular function leading to 
autophagy and apoptosis. It is important to understand and elucidate the mechanism by which 
folate deficiency has an effect on the mTOR signaling network in brain development and 
cognitive decline. It becomes crucial to understand how folate deficiency causes the pathway to 
become deregulated or over-enhanced to negatively impact brain development, cognition and 
memory. We hypothesize that dietary folate restriction alters the mTOR signaling network in the 
brain to provide protection against the onset and progression of neurodegenerative diseases.  
Specific Aim 1:  
To investigate if folate deficiency provides a protective role against factors contributing to 
neurodegenerative diseases in mice. 
Specific Aim 2:  
To examine the impact of folate deficiency within the mTOR signaling pathway to elucidate the 
signaling mechanisms of the substrates.  
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CHAPTER 3: METHODS 
Animals  
The experiments were performed in young adult (6 month), wild-type male C57BL/6 
specific pathogen-free mice in accordance with NIH guidelines for the use and care of laboratory 
animals. The Wayne State University Animal Investigation Committee approved the animal 
protocol. The mice were maintained on a 12-hr light/dark cycle and fed standard mouse chow 
and water ad libitum. At 12 weeks of age, the mice were randomly assigned to two dietary 
groups and were fed AIN93G-purified isoenergetic diets (Dyets, Inc., Lehigh Valley, PA). Diets 
were stored at –20°C. 1% succinyl sulfathiazole was added to all diets. The control group 
received a folate adequate diet containing 2 mg/kg folic acid. The experimental group received a 
folate-deficient diet containing 0 mg/kg folic acid. The animals' food intake and body weights 
were monitored twice weekly to monitor for signs of toxicity and the experimental diets were 
continued for 8 weeks. At 24 weeks, mice were anesthetized in a CO2 chamber and sacrificed by 
cervical dislocation. Harvested brain was flash frozen and stored in liquid nitrogen [4]. 
Whole Cell Extraction  
 Whole cell extraction was performed per standard protocol. 100 mg of brain tissue 
samples were extracted using a homogenizer. During the homogenizing process various, 
detergents were used: Igepal, Sodium deoxycholate, SDS, PBS, mainly to lyse the cells, denature 
some of the protein structures (but not fully damage the proteins), and to place a negative charge 
on the protein for it to be linearized. RIPA buffers were added to the brain tissue, it was 
homogenized, and thereafter the proteases were added to ensure protein solubility to inhibit any 
damages that may have been caused by the denaturing agents. Various spins were conducted as 
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protocol demands, to separate pellet from supernatant. The supernatant was the collected very 
carefully in a separate tube and put into -80ºC until ready to be used. 
Western Blot Analysis 
Western blot analysis was performed using 200 µg of crude nuclear extract isolated form 
brain tissue per standard protocol. To ensure the correct amount of protein concentration was 
used from each sample, the Bradford Assay was performed according to standard protocol and 
amounts were determined through normalization. Samples were then subjected to 
polyacrylamide gel electrophoresis (SDS-PAGE). Upon completion of SDS-PAGE, the region 
containing the protein(s) of interest was excised and prepared for western blot analysis while the 
remaining portion of the gel was stained with GelCode®Blue Stain Reagent (Pierce 
Biotechnology, Rockford, IL) to ensure equal protein loading. . Western blot analysis was 
conducted by using affinity purified polyclonal antisera developed against mouse target proteins. 
As an internal control for protein loading, membranes were reprobed with anti-Lamin B antibody 
(Santa Cruz Biotechnology, santa Cruz, CA). The bands were visualized and quantified using a 
ChemiImager® System (Bio-Rad, Hercules, CA) after incubation in SuperSignal® West Pico 
Chemiluminescent Substrate (Pierce Biotechnology, Rockford, IL). Data are expressed as the 
integrated density value (I.D.V.) of the band per µg of protein loaded [4]. 
Statistical Analysis 
 Statistical significance was determined using an “unpaired t-test”. P values less than 0.05 
were considered statistically significant.  
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CHAPTER 4: FIGURES  
Figure 4-1: Experimental Design 
 
 
Figure 4-1Experimental Design:  The control mice were given a folate adequate diet (2mg/kg 
body weight) and the experimental mice were given folate deficient diet (0mg/kg body weight). 
The animals' food intake and body weights were monitored twice weekly to monitor for signs of 
toxicity and the experimental diets were continued for 8 weeks. Mice were then sacrificed for 
analysis at 24 weeks. 
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Figure 4-2: Effect of folate adequate vs. folate restricted diet on protein levels of β-actin in 
C57BL/6 mice 
 
 
 
Figure 4.2 Effect of folate adequate vs. folate restricted diet on protein levels of β-actin in 
C57BL/6 mice: In the above figure, an analysis of β-actin protein levels in brain of young 
wildtype mice is shown. Experimental mice were given folate deficient diets as described 
previously while control mice were given a folate adequate diet. The protein levels were 
quantified using Western Blot analysis. Values represent an average (standard error of the mean) 
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an 
asterisk superscript indicates significant difference (p<0.05). Levels of β-actin were found to be 
statistically insignificant between control and experimental groups. T-test = 0.260963 
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Figure 4-3: Effect of folate adequate vs. folate restricted diet on protein levels of Beclin in 
C57BL/6 mice 
 
Figure 4.3 Effect of folate adequate vs. folate restricted diet on protein levels of Beclin in 
C57BL/6 mice: In the above figure, an analysis of Beclin protein levels in brain of young 
wildtype mice is shown. Experimental mice were given folate deficient diets as described 
previously while control mice were given a folate adequate diet. The protein levels were 
quantified using Western Blot analysis. Values represent an average (standard error of the mean) 
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an 
asterisk superscript indicates significant difference (p<0.05). Levels of Beclin show significant 
difference comparing control vs. experimental diets. T-test = 0.025006 
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Figure 4-4: Effect of folate adequate vs. folate restricted diet on protein levels of ATG7 in 
C57BL/6 mice 
 
Figure 4.4 Effect of folate adequate vs. folate restricted diet on protein levels of ATG7 in mice: 
In the above figure, an analysis of ATG7 protein levels in brain of young wildtype mice is 
shown. Experimental mice were given folate deficient diets as described previously while control 
mice were given a folate adequate diet. The protein levels were quantified using Western Blot 
analysis. Values represent an average (standard error of the mean) of data obtained from 4 mice 
of control group and 4 mice of experimental group. Values with an asterisk superscript indicates 
significant difference (p<0.05). Levels of ATG7 show no significant difference comparing 
control vs. experimental diets.T-test = 0.471038 
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Figure 4-5: Effect of folate adequate vs. folate restricted diet on protein levels of LC3 in 
C57BL/6 mice. 
 
Figure 4.5 Effect of folate adequate vs. folate restricted diet on protein levels of LC3 in 
C57BL/6 mice: In the above figure, an analysis of LC3 protein levels in brain of young wildtype 
mice is shown. Experimental mice were given folate deficient diets as described previously while 
control mice were given a folate adequate diet. The protein levels were quantified using Western 
Blot analysis. Values represent an average (standard error of the mean) of data obtained from 4 
mice of control group and 4 mice of experimental group. Values with an asterisk superscript 
indicates significant difference (p<0.05). Levels of LC3 show significant difference comparing 
control vs. experimental diets. T-test = 0.00054 
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Figure 4-6: Effect of folate adequate vs. folate restricted diet on protein levels of IPMK in 
C57BL/6 mice 
 
Figure 4.6 Effect of folate adequate vs. folate restricted diet on protein levels of IPMK in 
C57BL/6 mice: In the above figure, an analysis of IPMK protein levels in brain of young 
wildtype mice is shown. Experimental mice were given folate deficient diets as described 
previously while control mice were given a folate adequate diet. The protein levels were 
quantified using Western Blot analysis. Values represent an average (standard error of the mean) 
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an 
asterisk superscript indicates significant difference (p<0.05). Levels of IPMK show significant 
difference comparing control vs. experimental diets.  
T-test = 0.005604002 
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Figure 4-7: Effect of folate adequate vs. folate restricted diet on protein levels of REDD-1 in 
C57BL/6 mice 
 
Figure 4.7 Effect of folate adequate vs. folate restricted diet on protein levels of REDD-1 in 
C57BL/6 mice: In the above figure, an analysis of REDD-1 protein levels in brain of young 
wildtype mice is shown. Experimental mice were given folate deficient diets as described 
previously while control mice were given a folate adequate diet. The protein levels were 
quantified using Western Blot analysis. Values represent an average (standard error of the mean) 
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an 
asterisk superscript indicates significant difference (p<0.05). Levels of REDD-1 show significant 
difference comparing control vs. experimental diets.  
T-test = 0.002287696 
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Figure 4-8: Effect of folate adequate vs. folate restricted diet on protein levels of p-AMPK in 
C57BL/6 mice 
 
Figure 4.8 Effect of folate adequate vs. folate restricted diet on protein levels of p-AMPK in 
C57BL/6 mice: In the above figure, an analysis of p-AMPK protein levels in brain of young 
wildtype mice is shown. Experimental mice were given folate deficient diets as described 
previously while control mice were given a folate adequate diet. The protein levels were 
quantified using Western Blot analysis. Values represent an average (standard error of the mean) 
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an 
asterisk superscript indicates significant difference (p<0.05). Levels of p-AMPK show 
significant difference comparing control vs. experimental diets.  
T-test= 0.000874041 
 
 
  
26 
 
 
 
Figure 4-9: Effect of folate adequate diet vs. folate restricted on protein levels of p-AKT in C57BL/6 
mice 
 
Figure 4.9 Effect of folate adequate diet vs. folate restricted on protein levels of p-AKT in 
C57BL/6 mice: In the above figure, an analysis of p-AKT protein levels in brain of young 
wildtype mice is shown. Experimental mice were given folate deficient diets as described 
previously while control mice were given a folate adequate diet. The protein levels were 
quantified using Western Blot analysis. Values represent an average (standard error of the mean) 
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an 
asterisk superscript indicates significant difference (p<0.05). Levels of p-AKT show significant 
difference comparing control vs. experimental diets. T-test= 0.007345. 
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Figure 4-10: Effect of folate adequate vs. folate restricted diet on protein levels of p-S6K in 
C57BL/6 mice 
 
Figure 4.10 Effect of folate adequate vs. folate restricted diet on protein levels of p-S6K in 
C57BL/6 mice: In the above figure, an analysis of p-S6K protein levels in brain of young 
wildtype mice is shown. Experimental mice were given folate deficient diets as described 
previously while control mice were given a folate adequate diet. The protein levels were 
quantified using Western Blot analysis. Values represent an average (standard error of the mean) 
of data obtained from 4 mice of control group and 4 mice of experimental group. Values with an 
asterisk superscript indicates significant difference (p<0.05). Levels of p-S6K show significant 
difference comparing control vs. experimental diets. T-test= 0.001465474. 
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CHAPTER 5: RESULTS 
 Folate deficiency has been associated with neurodegenerative conditions in the elderly; 
previous studies have not focused on the effect folate deficiency has on young adult mice. There 
have been studies that have observed the influence of rapamycin and the mTOR pathway in the 
pathologies of neurodegenerative diseases. The mTOR pathway is stimulated by various 
environmental cues and regulates cell processes based on these external cues. It is important to 
understand and elucidate the mechanism by which folate deficiency causes the mTOR pathway 
to become activated or inhibited to attenuate the onset or progression of pathologies 
characteristic of neurodegenerative diseases. An experimental design was prepared in our 
laboratory to investigate if folate deficiency provides a protective role against factors 
contributing to neurodegenerative diseases via the mTOR pathway. An experimental folate diet 
prepared by Harrison et al., was used by our laboratory to conduct this study. This diet was tested 
in adult C57/BL6 mice; the mice were separated in two groups: one control and one 
experimental group at 3-4 weeks of age. Each group was fed its respective diet ad libitum for 8 
weeks and then sacrificed for analysis (Figure 4-1) as described in the materials and methods 
section. The samples were obtained from each animal by performing whole cell extraction as 
described in the materials and methods section. 
 To investigate the effect of the diet in the brain of these mice, a western blot protein 
analysis (as described in the methods section) was conducted. Figure 4-2 represents a trial 
conducted for the control protein, β-Actin, as expected consistent protein expression is observed 
in each sample. Autophagy plays a key role in the pathology and progression of Alzheimer’s, 
Parkinson’s and Huntington’s disease. Autophagy is a catabolic process used by cells to clear 
any damaged proteins and organelles to survive in changing environments. The next thee figures 
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focus on autophagy factors of the mTOR pathway.  Figure 4-3 displays the effect of folate 
deficiency on the protein Beclin1, a significant difference is observed between both control 
groups. Beclin1 plays a central role in autophagy and is also required for ATG5/ATG7 
dependent and independent autophagy [48]. A higher level of signaling is observed in the FD 
mice, therefore autophagy is being promoted. The observed expression of Beclin 1 suggests that 
autophagy is not being inhibited, hence possibly providing protection against the accumulation 
of Aβ and huntingtin protein aggregates in Alzheimer’s and Huntington’s respectively. In Figure 
4-4, the levels of ATG7 do not show a significant difference, however it can be observed that the 
FD mice have higher signaling outputs then the FA mice.  ATG7 is an E1-like activating enzyme 
which activates ATG12 for its conjugation with ATG5 and ATG8. ATG7 is required for 
mitophagy which contributes to regulate mitochondrial quantity and quality by eliminating the 
mitochondria to a basal level to fulfill cellular energy requirements and prevent the excess 
production of ROS (reactive oxygen species) [49]. It modulates the activity of p53/TP53 to 
regulate cell cycle and survival during metabolic stress. ATG7 also plays a key role in the 
maintenance of axonal homeostasis and the prevention of axonal degeneration [49]. This finding 
suggests that the animals are responding to the FD diet and perhaps compensating to survive by 
attempting to inhibit mTOR activity at some level. If the animals were on the diet for a longer 
period of time, we may be able to see a more significant difference between FA and FD animals. 
LC3 is used as another autophagy marker due to its ability to be involved with inner and outer 
membrane of the autophagosome. LC3 is synthesized as pro-LC3, which is the processed by 
ATG4 into its cytosolic form, LC3-I. During autophagosome formation, ATG3 and ATG7 
mediate the covalent linkage of LC3-I to phosphatidylethanolamine (PE), for it to be 
incorporated into autophagosome membranes. This process converts LC3-I into LC3-II 
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indicating autophagy activity [50]. Figure 4-5 displays the expression of protein levels of LC3, a 
significant difference is observed between both animal groups. However in western blot analysis 
two bands of the LC3 protein must be detected two signify cleavage and this was not observed. 
LC3-I is covalently linking to phosphatidylethanolamine (PE) to be converted into LC3-II 
because there is an indication of autophagy occurrence however the level of conversion may be 
very low. This may also explain the insignificant expression levels of ATG7 observed in these 
animals. Nonetheless, the findings as related to autophagy factors suggest that there are 
protective measures being observed against neurodegeneration.  
IPMK has been classified as a physiologic mTOR cofactor and it regulates nutrient amino 
acid signaling to mTORC1 [33]. IPMK mediates direct binding with mTOR through its unique 
amino terminus domain; it senses the level of amino acids present in the cell and activates mTOR 
[51].  Figure 4-6 indicates that there is a significant difference in the expression of IPMK levels, 
the FD group exhibits much higher expression indicating mTOR activation. An accumulation of 
amino acids may be inducing this increased expression of IPMK. REDD-I is an upstream 
repressor of mTORC1 and is induced by stress, hypoxia, serum and nutrient deprivation.  In 
Figure 4-7 the levels of expression of the REDD-I protein are higher in the control group than 
that of the experimental group. Lower expression of REDD-I in the experimental group suggests 
that the folate deficient diet is not creating a hypoxic environment; perhaps mTOR activity is not 
de-regulated. In Parkinson’s brains the increased expression of REDD-I has been proven to be 
detrimental as it leads to the death of dopaminergic neurons, therefore this finding suggests that 
the FD diet may be acting as a protective measure in PD. AMPK is a protein kinase which senses 
intracellular energy and becomes activated as a response to low nutrient availability and ATP 
depletion.  AMPK is an important regulator of protein synthesis and energy (lipid and 
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carbohydrate) metabolism. The activation of AMPK inhibits the mTORC1 cascade by interacting 
with raptor and activating TSC proteins to inhibit Rheb; consequently decreasing the level of 
mTORC1. Figure 4-8 displays lower p-AMPK levels in the experimental group. Indicating that 
AMP: ATP energy levels are sufficient, therefore potentially resulting in activation of the mTOR 
pathway. This finding correlates with the levels of protein of p-AKT and p-S6K expression 
observed in the FD diet animals.  
mTORC1 is activated by the PI3K/AKT pathway; under normal conditions AKT is 
responsible for cell proliferation and endurance. Figure 4-9 exhibits higher levels of p-AKT 
expression in the FD animals. AKT s473 phosphorylation is mTORC2 dependent. This implies 
that folate deficiency appears to increase mTORC2 activity as a compensatory mechanism to 
maintain insulin sensitivity and increase survival. The protein, p70S6K acts directly upon the 
mTORC1 complex and is responsible for increasing protein synthesis and cellular proliferation. 
mTOR and p70S6K pathways are important in the CNS as amino acids control cortical function 
through these pathways. Glutamate and leucine depend upon p70S6K to modulate synaptic 
signaling and food intake [36].Figure 4-10 displays the effect of the folate deficient diet on the 
protein S6K-1, a significant difference is observed in which the FD group exhibits higher 
expression levels of S6K-1, thereby rendering mTORC1 active. Some studies have proven that 
hyperactive signaling of mTOR can have detrimental effects in AD patients, nonetheless there 
have been studies which have proven that complete mTOR inhibition can be harmful too.  
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CHAPTER 6: DISCUSSION 
Folate deficiency has been studied extensively due to its association with chronic 
diseases, such as Alzheimer’s disease, cancer and cardiovascular disease. In this study we focus 
on the effect folate deficiency has on the onset and progression of neurodegenerative diseases in 
relation to the mTOR pathway. In response to the FD diet we observed up-regulation of 
autophagy, however increased expression of p-S6K and p-AKT contrary to decreased REDD-I 
and increased IPMK expression suggested mTOR activation. Higher autophagy occurrence was 
indicated by increased expression of Beclin and LC3. Interestingly enough, even though IPMK 
levels suggested mTOR inhibition, another upstream effector p-AMPK suggested mTOR 
activation. 
REDD-I, IPMK and AMPK are upstream effectors of the mTOR pathway. REDD-I is 
elevated during hypoxic conditions and nutrient deprivation, however the results indicate that 
folate deficiency is not creating a hypoxic environment therefore mTOR may not be effected by 
the expression of REDD-I. In Parkinson’s brains the increased expression of REDD-I has been 
proven to be detrimental as it leads to the death of dopaminergic neurons, therefore this finding 
suggests that the FD diet may be acting as a protective measure in PD.  IPMK expression is 
found to be elevated in the folate deficient mice, suggesting that mTOR activity is actually 
inhibited. One proposal for this behavior is that folate deficiency may be preventing protein 
synthesis by inhibiting mTORC1, which could subsequently lead to a buildup of amino acids. 
Leading to the over-expression of IPMK without stimulating mTORC1. Previous studies 
conducted in our laboratory with folate deficient mice have exhibited lower levels of amino acid 
and ATP. Phosphorylated AMPK acts as an energy sensor in the cell, inhibiting mTOR when 
energy is low. In nutrient deprivation conditions like folate deficiency, energy depletion is 
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expected and is expressed via p-AMPK levels. However in this study the expression of p-AMPK 
is interestingly found to be lower in the FD mice, indicating that ATP levels are sufficient, 
rendering mTORC1 active. The lower expression of p-AMPK observed in the folate deficient 
mice is an unexpected finding; perhaps since IPMK levels are higher there is a buildup of amino 
acids triggering sufficient ATP levels.  
The expression of Beclin, ATG7 and LC3 is higher in the folate deficient group, 
indicating higher levels of autophagy. The failure to induce autophagy has been associated with 
brain pathologies, hence the up-regulation of autophagy exerted by the folate deficient diet may 
be acting as a protective measure. The levels of Beclin and LC3 were found to be significant, 
however LC3 expression did not provide the two bands for analysis, suggesting slow conversion 
of LC3-I to LC3-II , thus autophagy is occurring but at a slow rate. Even though ATG7 levels 
were not found to be significant the observed results still show that the levels are higher in the 
folate deficient mice. This expression may be related to the lower conversion rate of LC3-I to 
LC3-II.  Autophagy causes the inhibition of the mTOR pathway, however the expression levels 
observed in p-S6K and p-AKT suggests that mTOR activation is occurring. p-S6K and p-AKT 
are both downstream effectors of the mTOR pathway. p-S6K is responsible for protein synthesis, 
cell proliferation and it increases the activity of glycogen synthase kinase, which increases 
glucose concentrations. We expected to observe a decrease in p-S6K levels due to the higher 
levels of autophagy observed. Possibly the lower level of REDD-I expression is relaying a 
message within the cell for S6K to not be phosphorylated since it is not in a hypoxic condition.  
This increase in p-S6K activity may be influencing p-AKT activity to be increased due to higher 
levels of glucose concentrations being sensed by the cell. Growth factors activate mTORC1 
indirectly by suppressing TSC1/2 function through phosphorylation of TSC2 by 
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PI3K/AKT/mTOR pathway.  In the FD animals, p-AKT may somehow be prevailing the 
signaling of REDD-I and IPMK to the TSC1/2 complex for mTOR activity to be inhibited via 
phosphorylation of TSC2.  
Our experiments indicate that there has been modulation of the mTOR pathway in the 
brain of young adult mice fed a folate deficient mice.  The observed results indicate that there 
may be an increase in autophagy that occurs in neuronal cells of mice treated with a folate 
deficient diet. On the contrary, a folate deficient diet seems to increase the flux of the mTOR 
pathway.  The confounding results of this study suggests that more research must be done to 
fully understand this relationship. Perhaps a study conducted with the animals on the diet for a 
longer period of time may provide further insight into these findings.  
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  Nutrient-gene interactions can significantly impact several cellular processes in the 
human body by altering important molecular pathways. Nutrition can affect brain structure, 
function and development throughout the life cycle; it can have a profound effect on cognition ad 
mental health leading to neurodegenerative diseases. It is important to elucidate the mechanisms 
by which diet can effect signaling pathways in the brain. The alteration of the mTOR pathway 
has been implicated to be involved in the pathophysiology of neurodegenerative diseases. Due to 
the established role of folate playing a role in modulating the mTOR pathway, we decided to 
investigate how folate deficiency alters mTOR signaling in the brain. We hypothesized that 
dietary folate restriction alters the mTOR signaling network in the brain to provide protection 
against the onset and progression of neurodegenerative diseases. In response to the FD diet we 
observed higher autophagy occurrence however increased expression of p-S6K and p-AKT 
contrary to decreased REDD-I and increased IPMK expression suggested mTOR activation. 
Higher autophagy occurrence was indicated by increased expression of Beclin and LC3. 
Interestingly enough, even though IPMK levels suggested mTOR inhibition, another upstream 
effector p-AMPK suggested mTOR activation. 
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